Valuation: SpringWorks Therapeutics, Inc.

Market Cap 3.54B 3.09B 2.86B 2.63B 4.96B 341B 5.07B 34.13B 13.42B 167B 13.3B 13.01B 575B P/E 2023
-7.09x
P/E 2024 -10.4x
Enterprise Value 3.09B 2.7B 2.49B 2.29B 4.32B 297B 4.42B 29.75B 11.7B 146B 11.59B 11.34B 501B EV / Sales 2023
362,507,725x
EV / Sales 2024 11,654,155x
Free-Float
97.93%
Yield 2023 *
-
Yield 2024 -
3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
89.75
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/01/2023
Compliance Officer - 01/01/2022
Investor Relations Contact - 01/08/2018
Date Insider Type Main position Quantity % Market Cap.
1/7/25 Issuer sale

General Counsel

397,427 0.5304%
1/7/25 Issuer sale

Chief Technology Officer

369,000 0.4924%
1/7/25 Issuer sale

Chief Technology Officer

151,946 0.2028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--%-.--%+61.03% 3.54B
-0.33%+1.83%+24.73%-5.89% 68.85B
+0.67%+0.93%+36.86%+194.41% 52.13B
+0.94%+39.60%+39.60%+39.60% 43.46B
+0.28%+1.99%-51.53%-53.35% 41.24B
-1.40%+3.43%+64.81%-25.61% 30.41B
-2.11%-9.45%+97.76%-50.61% 24.53B
+0.51%+0.46%+72.78%+86.41% 23.42B
+4.72%+4.60%+5.13%+198.24% 19.75B
-0.86%-1.99%+70.03%+124.61% 16.57B
Average +0.26%-0.52%+36.02%+56.88% 32.39B
Weighted average by Cap. +0.20%+0.08%+32.59%+47.70%

Financials

2023 2024
Net sales 5.45 4.76 4.39 4.05 7.63 524.55 7.8 52.5 20.65 256.91 20.46 20.01 884.39 191.59 167.43 154.5 142.41 268.42 18.45K 274.37 1.85K 726.33 9.04K 719.51 703.73 31.11K
Net income -325M -284M -262M -242M -455M -31.31B -466M -3.13B -1.23B -15.33B -1.22B -1.19B -52.78B -258M -226M -208M -192M -362M -24.86B -370M -2.49B -979M -12.17B -969M -948M -41.91B
Net Debt -656M -573M -529M -487M -918M -63.13B -939M -6.32B -2.49B -30.92B -2.46B -2.41B -106B -454M -397M -366M -337M -636M -43.72B -650M -4.38B -1.72B -21.41B -1.71B -1.67B -73.71B
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SWTX Stock